ClinicalTrials.gg
Active, not recruitingNCT06926491Updated Oct 8, 2026

Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia(AOBA Study)

A Phase 3 interventional study of KK8398 in Achondroplasia, sponsored by Kyowa Kirin Co., Ltd.. Active, not recruiting at 9 sites in Japan. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Kyowa Kirin Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2024, registered Apr 2025).
Updated Oct 8, 2026Now Active, not recruitingEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 11 studies in Achondroplasia with a site in Japan — 1 open to participants now, 4 under way, 3 of them phase 3. Achondroplasia · Japan.

Started
2024
the only one that year
Phase 3
3 of 11
none open now
Registered
10th of 11
by date
Lead sponsor
1 of 11
Kyowa Kirin Co., Ltd.

Among the 11 studies in Achondroplasia with a site in Japan, this one is the only one that started in 2024, is one of 3 in phase 3, and was the 10th registered.

Achondroplasia

47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.

Browse Achondroplasia studies →

Open to participants now

1 of the 11 studies in Achondroplasia with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Achondroplasia with a site in Japan, or all of them as a file.
02

Study summary

This trial will evaluate the efficacy of KK8398 on annualized height velocity after 52 weeks of repeated administration of KK8398 to patients with achondroplasia

03

Conditions studied

  • Achondroplasia

Browse trials for

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients who are between 2.5 and 17.5 years old of age at the time of provisional registration. Patients who meet certain criteria in terms of Tanner stage and bone age.
  2. Patients who have been diagnosed with achondroplasia through genetic testing.

Exclusion criteria

Exclusion Criteria:

  1. Patients who meet the criteria for a certain height determined by age and gender in the "Growth Chart for Patients with Achondroplasia" at the time of the pre-registration examination
  2. Patients who have received treatment with r-hGH or a CNP analogue within a certain period prior to the pre-enrollment examination.
  3. Patients who have had previous osteotomy or who are scheduled to undergo osteotomy or epiphyseal growth inhibition during the study period. Epiphyseal growth inhibition in which the plate was removed more than 26 weeks prior to the pre-registration examination will not be excluded if the patient has completely healed without sequelae, based on the judgment of the investigator or sub-investigator.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    KK8398

    Drug: KK8398

Interventions

  • DrugKK8398

    KK8398 will be administered.

06

What researchers measure

Primary outcomes

  1. Change from baseline in annualized height velocity

    Time frame: Pre-dose, Week 52

Secondary outcomes

  1. Height Z-score using growth tables in patients with achondroplasia and the change from baseline

    Time frame: Pre-dose, Week 52

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No — There is not a plan to make IPD available.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for May 2029, 53 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2025
First posted
Apr 13, 2025
StartActual
Dec 1, 2024
Primary completionEst.
May 31, 2029
CompletionEst.
May 31, 2031
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 8, 2026
Sites
1 site added, 1 site removed
Show site
  • Aichi Children's Health and Medical Center · Ōbu, Japan
Show 1 removed
  • Aichi Children's Health and Medical Center · Ōbu, Japan
Oct 8, 2026
Enrollment
6 (estimated)→13 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Aichi Children's Health and Medical Center · Ōbu, Japan
    Show 1 removed
    • Aichi Children's Health and Medical Center · Ōbu, Japan
    Enrollment 6 (estimated)→13 (actual)
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06926491
Responsible party
Sponsor
First posted
Apr 13, 2025
Start date
Dec 1, 2024
Primary completion
May 31, 2029 (estimated)
Completion
May 31, 2031 (estimated)
Last update
Oct 8, 2026

Study contacts

Yu Sato
study director · Kyowa Kirin Co., Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion